Introduction {#s0005}
============

Gastrointestinal stromal tumors (GIST) are the most common primary mesenchymal neoplasms of the gastrointestinal tract with an incidence of 7 to 20 per million [@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030]. Predominant locations are the stomach (60% to -70%) and small intestine (25% to 30%), less common sites are the large bowel (up to 5%) and the omentum/mesentery (up to 5%) [@bb0035], [@bb0040]. Key event of pathogenesis in GIST are gain of function mutations in the genes encoding the receptor tyrosine kinase KIT (80% to 90%) or platelet derived growth factor receptor α (PDGFRα) (5% to 10%) [@bb0045], [@bb0050], [@bb0055]. Prognosis of GIST and patient outcome is based on tumor size, mitotic rate and tumor location [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080]. Complete surgical resection is the primary and the only curative treatment for local GIST. Adjuvant therapy of the tyrosine kinase inhibitor (TKI) imatinib is recommended in high and intermediate risk GIST [@bb0085]. TKI application remains the treatment of choice for non-resectable GIST or metastatic disease either in the neo-adjuvant or primary setting [@bb0090], [@bb0095]. Clinical presentation of GIST is variable. Abdominal pain or discomfort, palpable abdominal mass or gastrointestinal hemorrhage are the mainly reported symptoms, mostly related to tumorsite. About 20% to 30% of GISTs are asymptomatic and therefore diagnosed incidentally (e.g. during surgical procedures for other diseases [@bb0040]).

GIST are reported to occur in association with other secondary neoplasms at rates of 14% to 25% [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120], [@bb0125]. The spectrum of additional malignancies varies among the most common cancers, such as colorectal cancer, prostate cancer, breast cancer and gastric cancer. However, there are also reports on additional neoplasms like hematological germ cell and neuroendocrine tumors [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120], [@bb0125]. So far data are limited on the impact of secondary neoplasms on GIST prognosis and/or patient outcome. The largest study including 783 patients of one institutional tumor registry reported a rate of secondary neoplasms in 20% [@bb0110]. In contrast, very recently 43% of secondary neoplasms have been reported of a GIST cohort including only 86 patients [@bb0130]. Systematic work is missing regarding patient outcome and the assessment of overall survival (OS), disease specific survival (DSS) and disease free survival.

Therefore, the aim of the present study was to elucidate comprehensively the frequency and the type of additional neoplasms in a large-scale cohort of patients with GIST with focus on disease prognosis and patient outcome.

Patients and Methods {#s0010}
====================

Patients {#s0015}
--------

This study included 836 patients with histologically confirmed diagnosis of GIST from the multi-center Ulmer GIST Registry from 2006 to 2011. These patients were registered in a multi-center network encompassing 18 oncological centers in South Germany, according to the User's Guide to Registries Evaluating Patient Outcomes and to the *St*rengthening (of) the *R*eporting of *Ob*servational Studies in *E*pidemiology (STROBE) Statement [@bb0135], [@bb0140], [@bb0145], [@bb0150], [@bb0155]. All cooperating centers are non restricted, open hospitals implicating neither demographic nor social or clinical selection bias. Patients diagnosed before 2006 were registered retrospectively. Since 2006 registration and follow up was intended to be prospectively. After obtaining patients' consent descriptive and clinical data were collected from medical records, by a personal patient contact and/or contact with the treating physicians. Patients with a multineoplastic syndrome (i.e. Carney triad, type 1 neurofibromatosis/NF-1, familial GIST etc.) were not included.

The following clinicopathological parameters have been assessed: age, gender, clinical manifestation, tumor localization, primary size, mitotic rate, risk classification according to Fletcher et al. [@bb0060], Miettinen et al. [@bb0080] and Joensuu et al. [@bb0075], histological subtype, immunohistochemical staining (KIT in all cases; other markers if available), treatment (surgical resection, extent of resection, TKI application). Main attention was focused on the occurrence of additional neoplasms (benign and/or malign) i.e. GIST patients with multiple tumors as well as secondary malignancies. Outcome measurements were metastases, tumor recurrence and death (GIST related or not). The patients were divided into two main groups: GIST patients with and without additional neoplasms. In order to ascertain center specific differences as selection bias, data from the single oncology center of the University Hospital of Ulm were compared with data from the multicenter Ulmer GIST registry.

The study was approved by the institutional ethics committee and all patients gave written informed consent (Study No.: 90 + 91/2006).

Statistical Analyses {#s0020}
--------------------

Patient characteristics between the groups were compared by χ^2^ or Fishers exact test. Estimates for disease-free-survival (DFS), disease-specific-survival (DSS) and overall-survival (OS) were obtained by the Kaplan-Meier method [@bb0160] and differences between Kaplan-Meier curves were investigated by the log-rank test (after Mantel-Cox or Breslow-test, respectively). For analyses of disease-specific survival, non GIST-related deaths were censored. If applicable, the Hazard Ratio (HR) and 95% confidence interval (95% CI) were calculated regarding tumor-related death and tumor recurrence and/or metastasis by applying univariate Cox proportional hazards regression models. To prove the most relevant findings of the univariate model and Kaplan-Meier analyses, an additional multivariate Cox proportional hazards regression model has been established considering the variables age, gender, mitotic rate, tumor size and location. Statistical analysis was performed using SPSS V19.0 (SPSS Inc., USA). A value of α \< .05 was considered to be significant.

Results {#s0025}
=======

Descriptive and clinical data for both cohorts are given in [Table 1](#t0005){ref-type="table"}. 836 GIST patients with a median age of 67.9 years (range 24.5-94.8 years) and a female to male ratio of 1:1 were included in all analyses. Most tumors were localized in the stomach (63.7%) followed by the small bowel (28.8%), and other tissues (7.5%) including colorectal (4.7%) and extra-gastrointestinal (1.5%) GIST. The most common clinical manifestation was abdominal pain (21.9%) followed by gastro-intestinal bleeding (21.2%) and weight loss (5.7%). 39.2% had no clinical symptoms and the GISTs were detected incidentally. Surgical resection was performed in 98% with R0 resection in 92.9% of patients. TKI treatment was used in 20.9% of GIST. Major cell morphology was spindle cell (83.2%), 16.8% showed a mixed or epithelioid pattern. Mean and median tumor size was 5.4 cm (± SD 4.7 cm) and 4.1 cm (0.3-40 cm). 16.8% and 70.3% of tumors showed a mitotic rate of ≥ 10/50 high power fields (HPF) and \< 5/50HPF, respectively. KIT staining was positive in 97.8%. Risk classifications according to Fletcher et al. [@bb0060] and Joensuu [@bb0075] (modified NIH-classification) resulted in high risk patients in 26.5% and 32.3%, respectively and in intermediate/low risk patients in 73.4% and 67.7%, respectively.Table 1Demographic and Clinicopathological Data of 836 GIST Patients with Additional Neoplasms**ParameterSingle center(*n* = 143)Multi center(*n* = 836)Epidemiology(*N*)%(*N*)%** Gender (male vs. female)(70/73)49.0/51.0(423/413)50.6/49.6 Mean age at diagnosis (year ± S.D.)64.7 (12.7)66.3 (12.3) Median age at diagnosis (year, range)66.7 (24.5; 94.1)67.9 (24.5; 94.8)**Localisation of GIST** Gaster/small bowel/other(84/48/9)59.6/34.0/6.4(519/235/61)63.7/28.8/7.5**Pathological parameters** Cell morphology (spindle vs. epithelioid/mixed)(116/13)89.9/10.1(618/125)83.2/16.8 Mean tumor size (cm)6.0 (5.6)5.4 (4.7) Median tumor size (cm)4.4 (0.4; 40.0)4.1 (0.3; 40) Mitotic rate (\< 5 vs. ≥ 5/50 HPF)(73/39)65.2/34.8(421/178)70.3/29.7 Mitotic rate (\< 10 vs. ≥ 10/50 HPF)(92/20)82.1/17.9(497/100)83.2/16.8 IHC KIT (pos vs. neg)(128/2)97.7/2.3(743/17)97.8/2.2 IHC CD34 (pos vs. neg)(98/21)82.4/17.6(544/73)88.2/11.8**Risk classification** NIH (high/intermediate/low/very low)(38/21/39/25)30.9/17.1/31.7/20.3(173/145/219/115)26.5/22.2/33.6/17.6 AFIP (high/intermediate/low/very low)(32/8/50/27)27.4/6.8/42.7/23.1(135/83/269/140)21.5/13.2/42.9/22.3 mod. NIH (high/intermediate/low/very low)(40/19/37/27)32.5/15.4/30.1/22.0(211/107/195/140)32.3/16.4/29.9/21.4**Clinical parameters** Resection (R0 vs. R1/2)(106/10)91.4/8.6(631/48)92.9/7.1 Multivisceral resections (yes vs. no)(31/112)21.5/78.5(194/642)23.2/76.8 TKI-Therapy (yes vs. no)(23/109)19.7/80.3(150/568)20.9/79.1 Incidental diagnosis (yes vs. no)(51/79)39.2/60.8(307/465)39.8/60.2**Secondary neoplasms** Rate of malignant neoplasms(60)42.0(267)31.9 Rate of benign neoplasms(30)21.0(209)25.0 Rate of malignant or benign neoplasms(81)56.6(422)50.5 Rate of multiple malignant NPL(11)7.6(45)5.3**Symptoms** Abdominal pain(44)46.8(172)21.9 GI bleeding(39)41.5(167)21.2 Weight loss(15)16.0(45)5.7**Survival analysis** Mean follow-up time (year ± SD)5.4 (3.9)4.5 (3.5) Median follow-up time (year, range)5.0 \[0.01; 18.5\]4.0 \[0.01; 23.2\] Death (total/GIST-related)(41/15)28.7/10.5(193/66)23.1/7.9 Rate of recurrence or metastases(30 of 135)22.1(146 of 761)19.2 Overall-survival-rates (1-/3-/5-year)(121/93/69)93.2/84.3/75.4(629/454/300)92.3/84.0/76.6 Disease-specific survival-rates (1-/3-/5-year)(121/93/69)97.6/93.1/88.7(629/454/300)97.3/94.3/90.9 Disease-free-survival rates (1-/3-/5-year)(105/77/57)86.4/80.9/78.5(526/366/239)88.9/84.8/81.9[^1]

Outcome Measurements {#s0030}
--------------------

Metastases or tumor recurrence occurred in 19.2% (*n* = 146 of 761 patients), while 11.2% (93 of 836 pts) of GIST patients had initial metastases. Median follow up-time until tumor recurrence or metastases in high-risk patients was 2.75 years (range 0.12; 22.6 yrs). 23.1% (*n* = 193) patients died, 66 of them (34.2%) due to GIST-related causes. 1-, 3- and 5-year OS were 92.3%, 84.0% and 76.6%, respectively. The 1-, 3- and 5-year DSS was 97.3%, 94.3% and 90.9%, respectively. The 1-, 3- and 5-year DFS was 88.9%, 84.8% and 81.9%, respectively. Five-year patient outcome for high risk versus non-high risk patients of the Ulmer multicenter registry was significantly reduced with a DSS of 78.4% vs. 95.8% (HR=7.17, CI 95% 3.56-14.45, *P* \< .001) and a DFS of 50.0% vs. 93.8% (HR = 9.54, 95% CI 5.82-15.62, *P* \< .001). OS was not different between both groups (71.8% vs. 80.8%).

GIST and Additional Malignancies {#s0035}
--------------------------------

In the Ulmer GIST registry (*n* = 836) additional neoplasms associated with GIST were found in 50.5% (422 patients with 579 malign and/or benign tumors; [Table 1](#t0005){ref-type="table"}). A total of 31.9 % of GIST showed malignant tumors (317 tumors in 267 patients). The median follow-up time was 4.0 years (range 0.01-23.2 years). In the single center cohort a total of 56.6% GIST patients showed additional neoplasms. Malignancies in addition to GIST occurred in 42.0% (60 of 143 patients with 73 tumors). The median follow-up time was 5.0 years (range 0.01 to 18.5 yrs). The detailed spectrum of additional secondary malignacies is given in [Table 2](#t0010){ref-type="table"}. Fourty-five GIST patients (5.3%) were affected by two or more tumors (Supplemental Table 1). Three of those patients had three and one patient even four malignant cancers. Detailed information of additional benign tumors are given in the Supplemental Table 2). Comparative analyses between both cohorts (single versus multi-center GIST cohort) showed no significant differences for clinicopathological data (i.e. tumor location, tumor size, mitotic rate, histological subtype, KIT positivity, resection extent and rate of TKI-application; [Table 1](#t0005){ref-type="table"}).Table 2Type and Frequency of Secondary Malignancies in Patients With GISTPresent study 2014Pandungeran et al. 2010Agaimy et al. 2006n**(*N*)**%**(*N*)**%**(*N*)**%**GI-cancers**(**138**)**43**.**5**(**48**)**25**.**8**(**228**)**46**.**9** Colorectal(68)21.5(18)9.7(109)22.4 Rectal cancer22 Colon cancer46 HBP NPL(20)6.3(8)4.3(20)4.1 Pancreas Cancer15 Gallbladder2 IPMN1 Cholangio carcinoma1 Ampullary cancer1 Esophagus and stomach(44)13.9(14)7.5(106)21.8 Stomach cancer33 Esophagus cancer11 Other GI Ca(6) Neuroendocrine-cancer4 Duodenal cancer1 Jejunal cancer1**Urological, gynaecologoical and breast cancer**(**108**)**34**.**1**(**77**)**41**(**129**)**29** Gynaecological tumor(61)19.2 Prostate cancer38 Uterus cancer12 Cervix cancer4 Ovarian cancer4 Uterus leiomyosarcoma2 Seminoma1 Urological cancer(21)6.6(18)9.7(37)7.6 Renal cell cancer12 Urothelial cancer9 Breast cancer(26)8.2(15)8.1(34)7.0**Blood-NPL**(**23**)**7**.**3**(**12**)**6**.**5**(**37**)**7**.**6** Multiple myeloma7 Lymphoma7 Chronic lymphatic leucemia5 Acute myeloid leucemia1 Poly cythemia vera2 Hairy cell leukemia1**Skin tumors**(**23**)**7**.**3**(**9**)**4**.**8**(**13**)**2**.**7** Squamous carcinoma10 Malignant melanoma8 others5**Lung tumors**(**8**)**2**.**5**(**10**)**5**.**4**(**26**)**5**.**4** Lung cancer7 Carcinoid1**others**(**17**)**5**.**4**(**31**)**16**.**6**(**49**)**10**.**1** Pheochromocytoma3 Thyroid cancer3 CUP2 Larynx cancer2 Oral cancer2 Malignant paraganglioma1 Osteosarcoma1 Leiomyosarcoma1 Glomus tumor (malignant)1 Uvea melanoma1(*n* = **295** own pts.)\
(*n* = **191** literature)**Total**(*n* = **317**)100%(*n* = **186**)100%(*n* = **486**)100%[^2]

Outcome of GIST *With* and *Without* Additional Malignancies {#s0040}
------------------------------------------------------------

The OS after 5 years in GIST patients with and without secondary malignancies was 62.8% and 83.4%, respectively indicating a significant difference (*P* \< .001 log-rank; *P* \< .001 Cox model, HR 0.397, 95% CI: 0.298-0.530; [Figure 1](#f0005){ref-type="fig"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}). Data regarding 5 year DSS were not different between both groups (90.8% and 90.9%, [Figure 2](#f0010){ref-type="fig"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}). The median survival time in GIST patients with and without secondary malignancies was 7.4 years (range 5.9-8.8) and 14.8 years (range 10.3-19.3), respectively. Detailed results are shown in [Table 3](#t0015){ref-type="table"}.Figure 1Overall survival in comparison of GIST patients with and without secondary malignancies.Figure 2Disease specific survival in GIST patients with and without secondary malignancy.Table 3Comparison of GIST Patients *With* and *Without* Second Malignancies**Parameter**(*n* = 267) With 2nd malignancies**(*n* = 569) without 2nd malignancy***P* value, (− test)**(*N*)%(*N*)%Epidemiology** Gender (male vs. female)(148/119)55.4/44.6*n* = 294/*n* = 27548.3/51.7%*P* = .056^1)^ Mean age at diagnosis (year, (± SD)69.3a (10.6)64.9 (12.9)*P* \< .001^2)^ Median age at diagnosis (year, \[range\])69.7 \[36.8; 94.8\]66.5 \[24.5; 93.3\]-**Localisation of GIST** Gaster/Small bowel/Other(172/72/21)64.9/27.2/7.9(347/163/40)63.1/29.6/7.3-**Pathological Parameters** Cell morphology (spindle vs. epithelioid/mixed)(198/31)86.5/13.5(420/94)81.7/18.3*P* = .110^1)^ Mean tumor size (cm, ± SD)4.1 (3.8)5.9 (5.0)*P* \< .001^2)^ Median tumor size (cm, \[range\])3.0 \[0.03; 20.0\]4.9 \[0.2; 40.0\]- Mitotic rate (\< 5 vs. ≥ 5/50 HPF)(136/45)75.1/24.9(285/133)68.2/31.8*P* = .087^1)^ Mitotic rate (\< 10 vs. ≥ 10/50 HPF)(153/27)85.0/15.0(344/73)82.5/17.5*P* = .452^1)^ IHC KIT (pos vs. neg)(237/3)98.8/1.3(506/14)97.3/2.70*P* = .211^1)^ IHC CD34 (pos vs. neg)(175/19)90.2/9.8(369/54)87.2/12.8*P* = .289^1)^**Risk Classification** NIH (high vs. Non-high risk)(41/162)20.2/79.8(132/449)29.4/70.6*P* = .014^1)^ AFIP (high vs. Non-high risk)(32/163)16.4/83.6(103/329)23.8/76.2*P* = .014^1)^ mod. NIH (high vs. Non-high risk)(52/151)25.6/74.4(159/291)35,3/64.7*P* = .014^1)^**Clinical parameters** Resection (R0 vs. R1/2)(198/13)93.8/6.2(433/35)92.5/7.5*P* = .535^1)^ TKI-Therapy (yes vs. no)(34/189)15.2/84.8(116/379)23.4/76.6*P* = .013^1)^ Incidental diagnosis (yes vs. no)(147/98)60.0/40.0(160/367)30.4/69.6*P* \< .001^1)^**Survival analysis** Mean follow-up time (year, (± SD)4.0 (± 3.2)4.7 (± 3.6)*P* = .016^2)^ Median follow-up time (year, \[range\])3.5 \[0.01; 18.5\]4.2 \[0.01; 23.2\]- Death (GIST-related vs. not)(19/98)7.1/36.7(47/95)8.3/16.7- Rate of recurrence or metastases(38)16.8(99)20,2*P* = .278^1)^ **Overall-survival-rates** (1-/3-/5-year)(194/135/88)**88.5/75.0/62.8**(435/319/212)**94.0/88.3/83.4*P* \< .001**^3)^ **Disease-specific survival** (1-/3-/5-year)(194/135/88)**99.0/96.5/90.8**(435/319/212)**96.6/93.4/90.9*P* = .603**^3)^ Disease-free survival (1-/3-/5-year)(159/108/66)90.7/88.1/82.7(367/258/173)88.1/83.4/81.5*P* = .586^3)^[^3]Table 4Comparative Survival Analyses of GIST Patients With and Without Secondary Malignancies(*N*~total~= 267/569)**With 2nd NPLWithout 2nd NPLUnivariate Cox modelMultivariate Cox model**%(*N*)%(*N*)*P*, HR (95% CI)*P*, HR (95% CI)**Disease-specific-survival** 1-year DSS**99.0**(194)**96.6**(435)*P* = .603, HR 1.164 (0.657;2.061)*P* = .880, HR 1.053 (0.536;2.070) 3-year DSS**96.5**(135)**93.4**(319) 5-year DSS**90.8**(88)**90.9**(212)**Overall-survival** 1-year OS**88.5**(194)**94.0**(435)***P*** \< .**001** HR 0.397 (0.298;0.530)***P*** \< .**001** HR 0.402 (0.282;0.575) 3-year OS**75.0**(135)**88.3**(319) 5-year OS**62.8**(88)**83.4**(212)**Disease-free survival** 1-year DFS**90.7**(159)**88.1**(367)*P* = .586 HR 1.118 (0.748;1.672)*P* = .616 HR 0.883 (0.544;1.435) 3-year DFS**88.1**(108)**83.4**(258) 5-year DFS**82.7**(66)**81.5**(173)[^4][^5]

Discussion {#s0045}
==========

In 2000, at the first time Maiorana et al. reported on a small series of epithelioid gastric GIST associated with additional neoplasms [@bb0165]. Kalmár et al. concluded a significantly higher secondary neoplasia rate in GIST in comparison to a Hungarian control population (21.7% vs 4%; *P* \< .001) based on 5 from 23 GIST patients with secondary malignancies and a follow-up time of 1--157 month. Mean age as well as the male to female ratio was similar in both groups [@bb0170]. Ruka et al. reported on 18 patients (10.0%) with a history of other malignancies among 180 GIST patients with a median age of 60 years whereby two GIST patients suffered from more than one other tumor [@bb0175]. In the same year Kövér et al. emphasized the high association of GIST with additional neoplasms, reporting of 7 from 43 GIST patients (16.3%) with secondary malignancies [@bb0180]. Agaimy et al. described 18.6% of GIST occurring secondary neoplasms (18/97 cases) with a female to male ratio of 2:1. GIST showed a trend towards small size (only 2 vs 18 large GIST), the majority of associated malignancies (50%) were classified as GI-cancers [@bb0185]. In 2006, Wronski et al. described a 14% rate of secondary neoplasms in GIST in 4/28 GIST patients [@bb0190]. A review of the literature and own cases by Agaimy et al. revealed 518 cancers in 486 GIST patients among a total of 4813 patients, accounting for secondary neoplasias and multiple neoplasias in 10.1% and 0.6% of GIST patients, respectively [@bb0100]. In the literature the reported frequency of additional neoplasms in GIST patients varies by 4.5% to 33% (mean 13%), and about half of them (47%) accounted for GI-cancers, followed by urogenital tumors. In the series of Liszka et al. 2007, 17 of 82 patients presented with secondary malignant neoplasia (20.7%) and a trend towards a small intestinal manifestation was found [@bb0105]. Focusing on immune-histochemical and mutational analysis, Arnogiannaki et al. 2010 reported no differences between GIST patients with (6 of 20 GIST) or without additional malignancy [@bb0195]. The largest clinical study, including 783 GIST patients, reports on 153 patients (20.3%) with additional malignancies [@bb0110]. Of interest 15.7% (*n* = 24/153) presented with synchronous and 84.3% (*n* = 129/153) with metachronous malignant neoplasms. A total of 20.9% GIST (*n* = 32/153) developed secondary malignancies (after the diagnosis of GIST) and 63.4% (*n* = 97/153) have had a history of previous malignancies however, without impact on the prognosis of GIST.

Taken together, the currently available data on additional neoplasms in GIST miss comprehensive information on patient outcome with regard to overall or disease specific and disease free survival. Therefore the present study, focused on the prognostic impact of additional neoplasms in GIST, investigating a large-scale multicenter cohort of 836 patients with GIST and in addition a single-center cohort of 143 GIST patients.

We observed 31.9% and 42.0% of GIST associated with additional malignancies by mean follow-up times of 4.5 years and 5.4 years, respectively. As expected the duration of the follow-up time was closely linked to the occurrence of secondary malignancies in GIST. In accordance with other studies, type of secondary malignancies encompasses the most common cancer entities such as GI cancers (43.5%) and urogenital and breast cancers (34.1%). Of note lung cancer (2.5%) was remarkable underrepresented [@bb0100], [@bb0105], [@bb0110], [@bb0130]. Within the three largest studies, the majority (75% to 80%) of GIST-associated tumors are gastrointestinal (25.8% to 46.6%) as well as urogenital and breast cancer (29% to 41%) [@bb0100], [@bb0110] ([Table 2](#t0010){ref-type="table"}).

The impact on prognosis of secondary malignancies is indicated by a significantly reduced five year OS rate of 62.8% compared to 83.4% in GIST patients without associated malignancies (*P* \< .001 log rank; *P* \< .001 Cox model, HR 0.397, 95% CI: 0.298; 0.530; [Figure 1](#f0005){ref-type="fig"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}). Five year DSS rates were identical (90.8% and 90.9%), demonstrating the importance of comprehensive outcome measures (e.g. OS vs DSS) in cancer patients.

Most GISTs associated additional malignancies occurred in patients who are 5 to 10 years older (*P* \< .001, *t* test) and they tend to fall into the low or very low risk category (*P* = .002, χ^2^-test), which is in accordance with the published data [@bb0100], [@bb0105], [@bb0110], [@bb0130]. The rate and spectrum of additional neoplasms (5% to 43%), the male to female ratio (58.3% males: 41.6% females to 42.1% males: 59.9% females) as well as the impact of second malignancies on the prognosis of GIST (none to significant) varies among several studies according to study size, duration of follow-up and comprehensiveness of survival analysis [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0130], [@bb0165], [@bb0180], [@bb0190]. These differences may also arise due to referral bias, different durations of follow up, study designs and comprehensiveness of survival analysis or simply due to different populations.

In accordance with Vassos et al. [@bb0130], the presented data confirm the major impact of GIST-associated malignancies on the prognosis of GIST and underpins the relevance of comprehensive outcome measurements. With regard to the 10 year survival probability, indicating an almost 50% difference between OS (38.4%) and DSS (86.8%) in the present study, we suggest a regular and continuous follow up of GIST patients at least for 10 years. Currently, pathophysiological mechanisms explaining the high risk of GIST patients for secondary malignancies are unknown which needs systematic basic as well as clinical research activities for the future. Moreover treatment strategies like the adjuvant TKI use in GIST may benefit from such kind of knowledge both for the selection of right patient and clinical outcome.

Appendix A. Supplementary Data {#s0065}
==============================

Supplemental Table 1. 41 GIST patients with two additional malignancies (out of 836 GIST patients of the Ulmer GIST registry).Supplemental Table 2. Benign secondary neoplasms associated with GIST in 207 of 836 patients.
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[^1]: SD, standard deviation; GI, gastrointestinal; TKI, tyrosine kinase inhibitor; IHC, immunohistochemistry.

[^2]: IPMN, Intraductal papillary mucinous neoplasm; CUP, Carcinoma of unknown primary.

[^3]: ^1)^ χ^2^-test, ^2)^*t* test, ^3)^ log-rank test.

[^4]: DSS, disease specific survival; DSF, disease free survival; OS, overall survival; HR, hazard ratio.

[^5]: Multivariate Cox proportional hazards regression model has been adjusted considering the variables age, gender, mitotic rate, tumor size and localization (GIST).
